We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.53%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.25B
AUM Growth
+$307M
Cap. Flow
+$95.8M
Cap. Flow %
2.95%
Top 10 Hldgs %
41.75%
Holding
101
New
19
Increased
28
Reduced
23
Closed
18

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$68.6M
2
ALLK
Allakos
ALLK
+$59.9M
3
WMGI
Wright Medical Group Inc
WMGI
+$58.6M
4
FATE icon
Fate Therapeutics
FATE
+$43.8M
5
REPL icon
Replimune Group
REPL
+$38.4M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.7M
2
WCG
Wellcare Health Plans, Inc.
WCG
+$56.5M
3
LH icon
Labcorp
LH
+$51.8M
4
INSM icon
Insmed
INSM
+$48.1M
5
CNC icon
Centene
CNC
+$39.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.24%
2 Miscellaneous 1.57%
3 Financials 1.28%
4 Energy 0.69%
5 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
76
Jazz Pharmaceuticals
JAZZ
$15.9B
$267K 0.01%
1,590
– –
FLXN
77
DELISTED
Flexion Therapeutics, Inc.
FLXN
$248K 0.01%
13,260
– –
SENS icon
78
Senseonics Holdings Inc
SENS
$493M
$214K 0.01%
2,245
-63,651
-97% -$5.21M
ACRS icon
79
Aclaris Therapeutics
ACRS
$885M
$164K 0.01%
11,320
-95,500
-89% -$1.64M
ADVM
80
DELISTED
Adverum Biotechnologies
ADVM
$135K ﹤0.01%
2,224
– –
CSLT
81
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$28K ﹤0.01%
10,229
– –
ABT icon
82
Abbott
ABT
$195B
– –
-449,300
Closed -$27.4M
ARAY icon
83
Accuray
ARAY
$32.7M
– –
-29,000
Closed -$119K
BHC icon
84
Bausch Health
BHC
$2.36B
– –
-8,930
Closed -$208K
CTMX icon
85
CytomX Therapeutics
CTMX
$699M
– –
-262,400
Closed -$6M
IMUX icon
86
Immunic
IMUX
$210M
– –
-2,738
Closed -$7.5M
INSM icon
87
Insmed
INSM
$25.9B
– –
-2,033,492
Closed -$48.1M
INSP icon
88
Inspire Medical Systems
INSP
$1.78B
– –
-200,000
Closed -$7.13M
IRTC icon
89
iRhythm Holdings
IRTC
$3.96B
– –
-401,303
Closed -$32.6M
LH icon
90
Labcorp
LH
$27.2B
– –
-335,698
Closed -$51.8M
SRPT icon
91
Sarepta Therapeutics
SRPT
$2.2B
– –
-31,100
Closed -$4.11M
TFX icon
92
Teleflex
TFX
$5.92B
– –
-79,886
Closed -$21.4M
UBX
93
DELISTED
Unity Biotechnology
UBX
– –
-25,040
Closed -$3.77M
ATYR
94
aTyr Pharma
ATYR
$53M
– –
-134,642
Closed -$1.72M
NVRO
95
DELISTED
NEVRO CORP.
NVRO
– –
-3,400
Closed -$271K
LUMO
96
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-179,083
Closed -$7.67M
VRAY
97
DELISTED
ViewRay, Inc.
VRAY
– –
-24,330
Closed -$168K
ALXN
98
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-489,300
Closed -$60.7M
HZNP
99
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-25,800
Closed -$427K
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2018 Portfolio in Review

As of Q3 2018, Redmile Group held 101 positions worth $3.25B, up 10% from $2.94B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group's Q3 2018 filing shows 19 new, 28 increased, 23 reduced and 18 closed positions. Its largest new stake was Cigna: 370,200 shares worth $77.1M. The largest sale was Alexion Pharmaceuticals, an estimated $60.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q3 2018 buy was Cigna: 370,200 shares worth $77.1M.
  • Redmile Group added most to Fate Therapeutics in Q3 2018, an estimated $43.8M increase.
  • Redmile Group's biggest Q3 2018 reduction was Wellcare Health Plans, Inc., cutting an estimated $56.5M.
  • Redmile Group fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $60.7M.
  • Redmile Group's ten largest holdings make up 42% of its $3.25B portfolio in Q3 2018.
  • Redmile Group opened 19 new positions and closed 18 in Q3 2018.
  • Redmile Group's portfolio value rose 10% quarter-over-quarter to $3.25B.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.